1. Search Result
Search Result
Results for "

CAFs

" in MedChemExpress (MCE) Product Catalog:

21

Inhibitors & Agonists

1

Peptides

1

Isotope-Labeled Compounds

2

Antibodies

1

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-175603

    Amine N-methyltransferase Cancer
    NCGC00685960 is a Nicotinamide N-methyltransferase (NNMT) inhibitor with an IC50 <10  nM. NCGC00685960 has potent antitumor activity. NCGC00685960 increases H3K27 trimethylation levels in ovarian cancer cells and inhibits α-SMA expression in NNMT-expressing ovarian fibroblasts. NCGC00685960 reduces 1-MNA levels, reverses SAM and H3K27 hypomethylation and significantly impairs collagen contractility in cancer-associated fibroblasts (CAFs). NCGC00685960 can be used for cancers research, such as ovarian cancer, breast cancer, colon cancer .
    NCGC00685960
  • HY-107588
    TC-I 15
    2 Publications Verification

    Integrin Cardiovascular Disease
    TC-I 15 (TC-I-15) is a type of allosteric collagen-binding integrin α2β1 inhibitor, and it also inhibits α1β1 and α11β1. TC-I 15 inhibits platelet adhesion to collagen and thrombus deposition. TC-I 15 prevents the formation of a pre-metastatic microenvironment by inhibiting the uptake of cancer-associated fibroblast (CAF) extracellular vesicles (EVs) by lung fibroblasts, which reduces the metastasis of salivary gland adenocystic carcinoma (SACC) to the lungs in mouse models, .
    TC-I 15
  • HY-114169
    WRG-28
    2 Publications Verification

    Discoidin Domain Receptor Inflammation/Immunology Cancer
    WRG-28 is a selective, extracellularly acting DDR2 allosteric inhibitor, with an IC50 of 230 nM. WRG-28 inhibits tumor invasion, migration and tumor-supporting effects of cancer-associated fibroblasts (CAFs). WRG-28 inhibits metastatic breast tumor cell colonization in the lungs. WRG-28 also shows good activity of relieving rheumatoid arthritis in CAIA model of mice .
    WRG-28
  • HY-178193

    DNA/RNA Synthesis Akt PD-1/PD-L1 Cancer
    Chem-0199 is an Adipocyte Enhancer-Binding Protein 1 (AEBP1) inhibitor. Chem-0199 can disrupt the interaction between AEBP1 and CKAP4, thereby enhances antitumor immunity. Chem-0199 can inhibit Akt phosphorylation (p-Akt) and downregulates PD-L1 expression. Chem-0199 can be used for the research of cancer, such as colon cancer .
    Chem-0199
  • HY-147895
    PCAF-IN-2
    2 Publications Verification

    Histone Acetyltransferase Apoptosis Cancer
    PCAF-IN-2 (compound 17) is a potent PCAF inhibitor with an IC50 value of 5.31 µM. PCAF-IN-2 shows anti-tumour activity. CAF-IN-2 induces apoptosis and arrest the cell cycle at the G2/M phase .
    PCAF-IN-2
  • HY-P10131

    Radionuclide-Drug Conjugates (RDCs) FAP Cancer
    3BP-3940 is a highly potent and selective peptide inhibitor of FAP that targets cancer-associated fibroblasts (CAFs) in the tumor microenvironment. 3BP-3940 can be labeled with radionuclides (such as Ga-68) for precise tumor imaging or Lu-177 for the development of targeted anticancer technologies. 3BP-3940 accumulates in tumor lesions and can be used to diagnose and inhibit various solid cancers and CAFs-related diseases .
    3BP-3940
  • HY-170872

    PROTACs DNA/RNA Synthesis Cancer
    PT-129 is a G3BP1/G3BP2 PROTAC degrader. PT-129 inhibits the formation of stress granules, disassembles pre-existing stress granules, disrupts stress granule-mediated ATF4 trafficking via migratory exocytosis, and suppresses cancer cell proliferation. PT-129 is applicable to the research of lung cancer and melanoma .
    PT-129
  • HY-155805

    CDK Cancer
    CAF-382 (compound B1) is an analog of SNS-032 and a CDKL5 and pan-CDK inhibitor with a weak GSK3α/β affinity (>1.8 μM) and inhibitory activity. CAF-382 inhibits CDKL5 and blocks the phosphorylation of the CDKL5 E2 domain .
    SGC-CAF382-1
  • HY-158970

    DNA/RNA Synthesis Cancer
    Caf1-IN-1 (Compound 8j) is inhibitor for ribonuclease Caf1 with an IC50 of 0.59 µM. Caf1-IN-1 is also a weak inhibitor for poly(A)-specific ribonuclease (PARN) with IC50 of 23.9 µM .
    Caf1-IN-1
  • HY-161248

    Microtubule/Tubulin Cancer
    E7130 is a microtubule inhibitor, which ameliorates the tumor microenvironment through suppression of cancer-associated fibroblasts (CAF) and promotion of tumor vasculature remodeling .
    E7130
  • HY-161346

    PROTACs Epigenetic Reader Domain Cancer
    EBET-1055 is a bromodomain and extra-terminal (BET) PROTAC degrader. EBET-1055 effectively inhibits the growth of pancreatic ductal adenocarcinoma (PDAC). EBET-1055 also simultaneously modulates cancer-associated fibroblast (CAF) activity, upregulating all reporter gene activities in organoid co-cultures . Pink: BET ligand (HY-161387); Blue: CRBN ligase ligand (HY-14658); Black: linker
    EBET-1055
  • HY-161346A

    PROTACs Epigenetic Reader Domain Cancer
    (Rac)-EBET-1055 is the racemate of EBET-1055 (HY-161346). EBET-1055 is a bromodomain and extra-terminal (BET) PROTAC degrader. EBET-1055 effectively inhibits the growth of pancreatic ductal adenocarcinoma (PDAC). EBET-1055 also simultaneously modulates cancer-associated fibroblast (CAF) activity, upregulating all reporter gene activities in organoid co-cultures .
    (Rac)-EBET-1055
  • HY-RS14270

    Small Interfering RNA (siRNA) Others

    TBX1 Human Pre-designed siRNA Set A contains three designed siRNAs for TBX1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    TBX1 Human Pre-designed siRNA Set A
    TBX1 Human Pre-designed siRNA Set A
  • HY-165386

    Toll-like Receptor (TLR) NF-κB STAT MMP COX VEGFR Cancer
    TU-100 is a Japanese herbal medicine. TU-100 exhibits anti-cancer effects by regulating cancer-associated fibroblasts (CAFs) in the TME. TU-100 can antagonize the M2 polarization phenotype of macrophages in the tumor microenvironment by suppressing the TLR4/NF-κB/STAT3 axis. TU-100 can inhibit the high expression of MMP-2, COX-2, and VEGF in TAMs .
    TU-100
  • HY-172063

    Cannabinoid Receptor Neurological Disease
    3-CAF is a synthetic cannabinoid featuring a 3-carboxylate-indazole structure.
    3-CAF
  • HY-114169S

    Isotope-Labeled Compounds Cancer
    WRG-28-d5 is the deuterium labeled WRG-28(HY-114169).WRG-28 is a selective, extracellularly acting DDR2 allosteric inhibitor, with an IC50 of 230 nM. WRG-28 inhibits tumor invasion, migration and tumor-supporting effects of cancer-associated fibroblasts (CAFs). WRG-28 inhibits metastatic
    WRG-28-d5
  • HY-163412

    IKK Inflammation/Immunology
    IKKβ-IN-3 (Compound hit4) is a IKKβ inhibitor with an IC50 value of 30.4 nM. IKKβ is a key enzyme in the NF-κB signaling pathway and is involved in the development of many diseases. IKKβ-IN-3 can be used in the study of CAF-induced arthritis .
    IKKβ-IN-3
  • HY-179577

    PIN1 Cancer
    PIN1 degrader-3 is a Pin1 (peptidyl-prolyl isomerase protein) (IC50 = 4.65 nM) degrader. PIN1 degrader-3 bound covalently to Pin1. PIN1 degrader-3-induced Pin1 degradation reduced cell viability, with EC50 values after 72 h of 8.4 μM in MIA PaCa-2 cells and 5.3 μM in KPC cell lines.PIN1 degrader-3 can destabilize Pin1 in vitro, causing its degradation in cells. PIN1 degrader-3 can be used for the study of pancreatic cancer .
    PIN1 degrader-3
  • HY-107588R

    Reference Standards Integrin Cardiovascular Disease
    TC-I 15 (Standard) is the analytical standard of TC-I 15 (HY-107588). This product is intended for research and analytical applications. TC-I 15 (TC-I-15) is a type of allosteric collagen-binding integrin α2β1 inhibitor, and it also inhibits α1β1 and α11β1. TC-I 15 inhibits platelet adhesion to collagen and thrombus deposition. TC-I 15 prevents the formation of a pre-metastatic microenvironment by inhibiting the uptake of cancer-associated fibroblast (CAF) extracellular vesicles (EVs) by lung fibroblasts, which reduces the metastasis of salivary gland adenocystic carcinoma (SACC) to the lungs in mouse models, .
    TC-I 15 (Standard)
  • HY-179535

    TAM Receptor Discoidin Domain Receptor TGF-β Receptor Hedgehog Cancer
    Axl-IN-21 is an orally active and selective AXL inhibitor (Kd = 2.7 nM, IC50 = 4.0 nM). Axl-IN-21 displays kinase selectivity and retains strong activity against cancer-related mul-kinases (Mer with Kd = 1.4 nM, DDR1 with IC50 = 22.2 nM, HIPK4 with Kd = 11.0 nM and LOK with Kd =10 nM). Axl-IN-21 overcomes tumor microenvironment-driven resistance by blocking CAF-derived GAS6-induced AXL/STAT3/ABCG1 signaling, restoring chemosensitivity and inhibiting drug efflux in gastric cancer (GC). Axl-IN-21 suppresses TGF-β1-induced epithelial-mesenchymal transition (EMT), migration, and invasion in MDA-MB-231 cells. Axl-IN-21 exhibits no significant cytotoxicity in non-cancerous cells. Axl-IN-21 can be research for triple negative breast cancer and gastric cancer [1] [2] .
    Axl-IN-21
  • HY-182272

    FAP Cancer
    FAP-IN-9 (compound P12) is a fibroblast activation protein (FAP) inhibitor with an IC50 of 0.38 nM against human FAP. FAP-IN-9 functionally inhibits FAP activity, and its specific binding is verified by in vitro and in vivo blocking assays. FAP-IN-9 forms stable complexes and acts as a tumor-targeting agent. When labeled with 99mTc, FAP-IN-9 serves as a SPECT probe and is applicable to research related to glioblastoma .
    FAP-IN-9

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: